# Differentiated tumor immune microenvironment of Epstein–Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy

## SUPPLEMENTARY MATERIALS



**Supplementary Figure 1: Kaplan-Meier method log-rank testing for 5-year overall survival (OS) by Programmed death 1 (PD-1) expression in gastric cancer.** PD-1 expression had no correlation with 5-year OS in complete cohort. ([HR] was 1.10, 95% confidence interval was 0.89 to 1.37, p=0.364).

**Supplementary Figure 2: Kaplan-Meier method log-rank testing for 5-year overall survival by CD8+ cell infiltration in Epstein-Barr virus-associated gastric cancer.**

**Supplementary Figure 3: The percentage of CD4$^+$, CD8$^+$, Foxp3$^+$ cell infiltration and PD-1 and PD-L1 expression in different AJCC stages of gastric cancer.** The number of patients in each subgroup was under X-axis and the positivity in different AJCC stages was labelled above each bar.

*[1]p=0.022, *[2]p=0.026, *[3]p=0.029, *[4]p=0.044;

**[1]p=0.003, **[2]p=0.002, **[3]p=0.002, **[4]p=0.002, **[5]p=0.008, **[6]p=0.008;

***[1]p<0.001, ***[2]p<0.001, ***[3]p=0.001.

Bonferroni correction for multiple comparisons was applied, two side.

CD4, cluster of differentiation 4; CD8, cluster of differentiation 8; Foxp3, Forkhead box P3; PD-1, programmed death 1; PD-L1, programmed death ligand-1;

AJCC, American Joint Committee on Cancer

**Supplementary Table 1: Clinicopathological characteristics of the patient populations**

See Supplementary File 1

**Supplementary Table 2: Clinicopathological characteristics of patients by different markers**

See Supplementary File 2